Case Name: In re: Nexium (esomeprazole) Antitrust Litigation
Docket No.: 1:12-md-02409
filed:August 24, 2012
court:U.S. District Court, District of Massachusetts
The Nexium case was filed in the Eastern District of Pennsylvania on August 24, 2012. The case was consolidated with related actions and transferred to the District of Massachusetts. One of the most prescribed drugs in America, Nexium is a prescription drug for the healing and maintenance of erosive esophagitis and treatment of symptomatic gastroesophageal reflux disease (heartburn).
The Nexium complaint alleges that defendants engaged in anticompetitive conduct by entering into so-called “pay for delay” agreements that delayed for more than six years less expensive generic equivalents of the drug, preserving for AstraZeneca up to approximately $3 billion per year in monopoly revenue. Plaintiffs allege that defendants’ unlawful conduct robbed consumers and health plans of the benefits of generic competition, forcing them to pay hundreds of millions more for a drug at artificially inflated prices.